Vaughn James J 4

Accession 0001209191-19-045631

CIK 0001131324other

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 7:08 PM ET

Size

24.4 KB

Accession

0001209191-19-045631

Form 4

Period: 2019-08-08

Chief Commercial Officer

Transactions

Sale
Common Stock
2019-08-08$74.20/sh−403$29,903→ 19,417 total
Exercise/Conversion
Common Stock
2019-08-08$33.21/sh+1,103$36,631→ 17,917 total
Sale
Common Stock
2019-08-08$73.57/sh−700$51,502→ 19,820 total
Sale
Common Stock
2019-08-08$73.56/sh−1,723$126,748→ 17,694 total
Sale
Common Stock
2019-08-08$74.21/sh−1,277$94,770→ 16,417 total
Exercise/Conversion
Employee Stock Option (right to buy) Holding
2019-08-08−1,103→ 45,707 total
Exercise: $33.21Exp: 2028-01-31→ Common Stock (1,103 underlying)
Sale
Common Stock
2019-08-08$72.80/sh−397$28,902→ 20,520 total
Exercise/Conversion
Common Stock
2019-08-08$31.12/sh+397$12,355→ 16,814 total
Exercise/Conversion
Common Stock
2019-08-08$31.12/sh+3,000$93,360→ 20,917 total
Exercise/Conversion
Employee Stock Option (right to buy) Holding
2019-08-08−397→ 6,000 total
Exercise: $31.12Exp: 2025-02-13→ Common Stock (397 underlying)
Exercise/Conversion
Employee Stock Option (right to buy) Holding
2019-08-08−3,000→ 3,000 total
Exercise: $31.12Exp: 2025-02-13→ Common Stock (3,000 underlying)

Footnotes (11)

[F1]Includes an aggregate of 11,281 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
[F10]The option became exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter.
[F11]The option becomes exercisable as to 25% of the shares on January 31, 2019, and becomes exercisable as to 1/48th of the shares each full month thereafter.
[F2]These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 11, 2019.
[F3]Represents actual sale price.
[F4]Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
[F5]Represents weighted average sale price. Actual sale prices ranged from $73.03 to $73.97.
[F6]Represents weighted average sale price. Actual sale prices ranged from $74.13 to $74.31.
[F7]These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
[F8]Represents weighted average sale price. Actual sale prices ranged from $72.99 to $73.92.
[F9]Represents weighted average sale price. Actual sale prices ranged from $73.99 to $74.42.

Documents

1 file

GENOMIC HEALTH INC

CIK 0001131324

Entity typeother